An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization. - Wikidata - wikimedia - TriplyDB

An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.

An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.

http://www.wikidata.org/entity/Q34580057

about

Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6 Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo Herkinorin analogues with differential beta-arrestin-2 interactions The effects of herkinorin, the first mu-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates Kappa-opioid ligands in the study and treatment of mood disorders Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position Structure-based discovery of opioid analgesics with reduced side effects.Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessors Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators Activation of mu opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) via β-arrestin-2-mediated cross-talk Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation Salvinorin A analogs as probes in opioid pharmacology.Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.A high-throughput screening system for G-protein-coupled receptors using β-lactamase enzyme complementation technology Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.Teaching old receptors new tricks: biasing seven-transmembrane receptors.Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.Unusual hemiacetal structure derived from Salvinorin A.Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo The potential for selective pharmacological therapies through biased receptor signaling Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.Exploring a role for heteromerization in GPCR signalling specificity.Agonist-selective mechanisms of GPCR desensitization Opioid receptor desensitization: mechanisms and its link to tolerance Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A Prolonged morphine treatment alters δ opioid receptor post-internalization trafficking A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation.Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.Inhibition of EGF-induced ERK/MAP kinase-mediated astrocyte proliferation by mu opioids: integration of G protein and beta-arrestin 2-dependent pathways.Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons.Distribution and trafficking of the μ-opioid receptor in enteric neurons of the guinea pig.A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling.

P2860

Q24643003-1D06855F-9F10-4359-9AD1-89791CB6E9C2 Q24646270-E8E3E351-CC2F-49F7-B757-B194E0A6BAC3 Q24646341-4399A5F8-3228-4697-BDAC-7E3468255CD0 Q24647416-E0115C30-0E11-4669-BA9C-8BECF04986DE Q24649793-7ACF29ED-5F07-44C2-94AE-03C049F3E864 Q24652924-660AD5C2-81F1-4E4C-980F-5EEB08D9E733 Q24657982-4E95711A-8B95-4E8C-8658-26732F94D2A9 Q24681800-43A60646-B0F2-473E-88FB-389E074A6A57 Q26331003-279FA4B6-8039-4CF0-9457-70020EBCE831 Q27005640-9192EAFF-2704-4E05-ACA7-03F917AC5CEE Q28275620-A7AF15DB-E957-49D7-A3FE-DCA655F72E19 Q28541771-4D18D9B7-34F2-43F5-9FA5-64E3868EC0D4 Q28551517-0E297764-AB3C-4650-9F2E-39D7EC58E563 Q30439719-ACAC76B5-C974-49AB-9BAC-2D66EB1826D8 Q30467220-3559C42C-A952-491A-ACD5-00B821555352 Q33651029-1F80E4C5-A389-4D37-A1FB-75A3986B102D Q33753871-B6EDA882-F9ED-4487-ADEA-4E0AB9F44795 Q33815047-ACAA13D5-A7AD-432D-B72E-2D80BB5FB4E7 Q33890786-FAF5942E-BEAA-4355-A8BD-5949EAF4A9A2 Q33985759-187E8DCD-CB26-4BE3-94DC-0307A05146A1 Q34061067-C530BA72-E3F8-4111-88C1-D78D67D694E2 Q34229894-75B3084B-F0B5-4721-833D-4CCCD9B721CD Q34401390-3673F94F-9F92-4F60-9A29-68811E0BDF0F Q34402623-81834BDC-3BF7-4047-B848-D56F55E8DCF4 Q34402658-7702203C-81C6-4601-B791-B8B31AC4A810 Q34547230-FF003140-E988-4ACA-BC98-BAAE4ED1AE3D Q34660378-4EAA35AA-1B98-4E61-90BE-283F81372FB4 Q34722029-68BECF3E-F529-46D6-946A-AB9ECC6435FE Q34729984-53F3C49F-18E6-4F8D-B0ED-C1FA3E74D5A1 Q34796464-5E13E1DA-4158-4E95-B5E4-429CC1F85B67 Q34939810-43BD30B9-A862-4808-A6FA-755268100919 Q34939888-DB6E1DD7-A387-490A-B1A9-77AF1EED2881 Q35066670-607455FB-A30C-4055-A6EB-608774DD24EA Q35213193-4162265F-D282-4F73-85ED-A61A6D69666C Q35264421-D1E526A0-EA13-40A1-9864-CF1C9068511C Q35609910-7444E757-1BEB-47C3-B53F-8A1528DC9CFB Q35763177-1F6BD3F6-7E09-4A31-92EB-17991549314B Q36025329-B460C91F-725F-4E10-B8C9-803CE8D46126 Q36065514-7402B42C-6948-4621-B97C-F173ACB3B7DC Q36082162-A6300FD0-1435-4B00-BE92-33146AC8888B

P2860

An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.

http://www.wikidata.org/entity/Q34580057

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

An opioid agonist that does no ...... s or receptor internalization.

@ast

An opioid agonist that does no ...... s or receptor internalization.

@en

An opioid agonist that does no ...... s or receptor internalization.

@nl

type

label

An opioid agonist that does no ...... s or receptor internalization.

@ast

An opioid agonist that does no ...... s or receptor internalization.

@en

An opioid agonist that does no ...... s or receptor internalization.

@nl

prefLabel

An opioid agonist that does no ...... s or receptor internalization.

@ast

An opioid agonist that does no ...... s or receptor internalization.

@en

An opioid agonist that does no ...... s or receptor internalization.

@nl

P1433

Q34580057-6001EB9A-2570-45BA-858E-F23412662E3B

P1476

Q34580057-EF72B18B-5186-4724-9657-9452E0192C1E

P2093

Q34580057-0B8AA713-0988-47C0-ABAC-F3233564ED3C

Q34580057-131B77BA-DB0D-41FD-88E2-3633A09DDC23

Q34580057-569AC52D-CE02-470B-8B08-F55E32439A44

Q34580057-5E541886-4574-4BD2-ACC4-A46FE4C4A515

Q34580057-65B387BC-26DC-4076-827D-6980F2B1CD41

Q34580057-9BAB49F4-50A2-43AF-B19C-69BC29664217

Q34580057-C9DB22EC-818C-44DA-A927-102CFEAFC067

P2860

Q34580057-021F868E-41E9-4537-9AE4-56DDB236FB6B

Q34580057-1607E162-2A09-4749-A374-3CD4E132A4BA

Q34580057-174C3F61-2B01-4BB3-8CA4-F6A81D9C5F7C

Q34580057-17CB8F1B-50E4-41AC-992D-0A32CC45EC2D

Q34580057-1B5C4DE8-F0C5-488C-9E65-A736683560AD

Q34580057-1DE2C764-59D0-4B02-B64F-63683A377F55

Q34580057-2AD1A167-786A-408F-A33A-14ACE400C312

Q34580057-2AE24DCA-D800-41F5-8D46-3E96FA91C9EB

Q34580057-2C47A861-8FFA-419D-8834-DE4DBD034C3B

Q34580057-2C71005E-423E-45D8-970C-B875329BE98F

P304

Q34580057-C8F27D3F-1068-4D0A-9F2E-961F84FDFE7C

P31

Q34580057-26693E4B-8558-432B-B8DC-BF2E259E24A0

P356

Q34580057-928C9BB1-95CB-49C1-BEAF-766923643F43

P433

Q34580057-81EC985B-7682-43C4-A5BB-146B6090EA50

P478

Q34580057-2355D99B-C5A4-473A-AA53-CA9FB054E0B7

P577

Q34580057-43A1B79C-AD80-4BD9-ABBB-E9A2ABC7337B

P5875

Q34580057-DC84D6A2-2447-43FB-AC90-70E58D0A6CB0

P698

Q34580057-7744BD9E-7A37-4C59-91C2-C7384362ACE1

P921

Q34580057-C3096B1F-2130-488F-942C-DBF5981B61C8

P932

Q34580057-0363A329-47E8-4219-A2E7-CBCE4F1D9730

P356

P1433

Molecular Pharmacology

P1476

An opioid agonist that does no ...... s or receptor internalization.

@en

P2093

C E Groer

http://www.w3.org/2001/XMLSchema#string

K Tidgewell

http://www.w3.org/2001/XMLSchema#string

L M Bohn

http://www.w3.org/2001/XMLSchema#string

R A Moyer

http://www.w3.org/2001/XMLSchema#string

R B Rothman

http://www.w3.org/2001/XMLSchema#string

T E Prisinzano

http://www.w3.org/2001/XMLSchema#string

W W Harding

http://www.w3.org/2001/XMLSchema#string

P2860

Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist

Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade

Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-beta-arrestin complexes after receptor endocytosis*

Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations

Enhanced morphine analgesia in mice lacking beta-arrestin 2

beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking

Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons

Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence

Specific G protein activation and mu-opioid receptor internalization caused by morphine, DAMGO and endomorphin I

Threonine 180 is required for G-protein-coupled receptor kinase 3- and beta-arrestin 2-mediated desensitization of the mu-opioid receptor in Xenopus oocytes.

P304

549-557

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/MOL.106.028258

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6705985

http://www.w3.org/2001/XMLSchema#string

P698

17090705

http://www.w3.org/2001/XMLSchema#string

P921

P932

3926195

http://www.w3.org/2001/XMLSchema#string